Pharma BD Deal Intelligence
A slow-burn platform validation: Eli Lilly's $37M-upfront, up-to-$694M metabolic GPCR alliance with Sosei Heptares has hit two development milestones by April 2026, with Nxera's NxWave structure-based design proving out against Lilly's diabetes targets.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Eli Lilly will work with Japan-based Sosei Heptares on small molecule drugs for diabetes and metabolic diseases targeting G-protein coupled receptors, the…
Eli Lilly has signed a multi-target collaboration and license agreement with Sosei Heptares to discover and develop GPCR-targeting small molecules for diabetes…
Nxera Pharma achieved a SECOND development milestone in its collaboration with Eli Lilly targeting metabolic diseases (undisclosed payment). The milestone…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Sosei Heptares and Eli Lilly entered a multi-target collaboration and license agreement in diabetes and metabolic diseases leveraging Sosei's GPCR-focused StaR/SBDD platform. Sosei received $37M upfront with up to $694M in development and commercial milestones plus tiered royalties on global sales. Since signing, the collaboration has advanced: now-renamed Nxera Pharma (formerly Sosei Heptares) achieved a first development milestone (announced 1 June 2025, undisclosed payment, expected Q3 FY2025) and a second development milestone (announced 8 April 2026, undisclosed payment), both validating its NxWave (formerly StaR/SBDD) GPCR structure-based platform against the metabolic targets. Lilly leads development and commercialization; Nxera remains eligible for up to $694M in remaining development and commercial milestones plus tiered royalties. The collaboration is active and progressing as of June 2026.
37M US cases/yr · $85.0B Global diabetes market 2022 · ~$730M Total deal BD value (up to, incl. milestones)
The Lilly-Sosei Heptares collaboration targets undisclosed GPCR-driven metabolic indications, with type 2 diabetes (T2D) and obesity as the strategic anchor. T2D affects approximately 37 million U.S. adults (11.3% prevalence), with another 96 million pre-diabetic, while obesity affects roughly 100 million U.S. adults (BMI greater than 30). The metabolic disease commercial market is in the middle of the most disruptive cycle in its history, driven by GLP-1 receptor agonists Ozempic/Wegovy (semaglutide, Novo Nordisk) and Mounjaro/Zepbound (tirzepatide, Lilly's GIP/GLP-1 dual agonist). GPCR drug discovery is the backbone of the metabolic franchise — incretin receptors (GLP-1R, GIPR, GCGR), apelin receptors, and oxyntomodulin/glucagon-receptor families are all class A GPCRs. Lilly's strategic interest in Sosei Heptares' StaR (Stabilized Receptor) and structure-based drug design (SBDD) platform is to extend its incretin franchise leadership beyond tirzepatide via novel GPCR targets including potential oral small-molecule incretin agonists, GPR142, and undisclosed metabolic GPCRs. WAC pricing for branded incretin therapies is approximately $1,000-1,400 per month, with U.S. payer coverage rapidly broadening across Medicare, commercial, and increasingly Medicaid.
The metabolic GPCR competitive landscape is anchored by injectable incretin receptor agonists. Mounjaro/Zepbound (tirzepatide, Lilly) is the dual GIP/GLP-1 agonist setting new efficacy benchmarks (-20-22% body weight in SURMOUNT trials). Ozempic/Wegovy (semaglutide, Novo Nordisk) is the GLP-1R franchise leader at over $20B annual revenue. Trulicity (dulaglutide, Lilly) is in long-tail decline as patients switch to tirzepatide. Next-generation pipeline competitors include orforglipron (oral non-peptide GLP-1, Lilly Phase 3), retatrutide (GLP-1/GIP/GCG triple agonist, Lilly Phase 3), CagriSema (semaglutide + amylin analog, Novo Phase 3), and amycretin (GLP-1/amylin, Novo Phase 1/2). GPCR-platform competitors include Structure Therapeutics' GSBR-1290 (oral GLP-1, Phase 2), Carmot/Roche CT-388 (dual GIP/GLP-1), and Altimmune's pemvidutide (GLP-1/GCG). Sosei Heptares' StaR/SBDD platform sits upstream as a discovery enabler — the deal positions Lilly to extend leadership into novel metabolic GPCRs beyond the validated incretin axis.
Nxera Pharma (formerly Sosei Heptares) announced a first development milestone under the 2022 Lilly GPCR metabolic-disease collaboration, triggering an undisclosed payment expected in Q3 FY2025. Remaining eligibility unchanged at up to $694M plus royalties.
Nxera Pharma announced a second development milestone in the Lilly metabolic-disease collaboration (undisclosed payment), validating its NxWave GPCR structure-based platform. Lilly leads development; Nxera eligible for up to $694M in remaining milestones plus royalties.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Sosei Group Corp. (Sosei Heptares) (this deal) | 2022 | $730M | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2022 deals · Eli Lilly and Company deals · Metabolic deals